Identification of Non-gal, Non-HLA Antigens in Patients Implanted with Xenogenic Material


About this study

The purpose of this study is to identify non-HLA and non-gal protein antigens in transplanted xenogenic tissues (ie bovine or porcine pericardial heart valves) that can then be used to preemptively identify and overcome graft-specific immune responses.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients who will receive either a biological or mechanical heart valve.

Exclusion Criteria: 

  • Current diagnosis or currently receiving therapy for malignant cancer, current diagnosis of benign cancer if treatment with concurrent radiotherapy and/or chemotherapy is indicated, cancer in remission for less than 5 years if previously treated with radiotherapy and/or chemotherapy,  autoimmune diseases, previous tissue valve implants, or current pregnancy.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Leigh Griffiths, Ph.D., MRCVS

Open for enrollment

Contact information:

Grace Bourassa

(507) 255-5782

Jacksonville, Fla.

Mayo Clinic principal investigator

Peter Pollak, M.D.

Open for enrollment

Contact information:

Patricia Aggen

(507) 266-2123

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Said Alsidawi, M.D.

Open for enrollment

Contact information:

Miranda Hirschi RPSGT

(480) 342-1328

More information


Publications are currently not available

Mayo Clinic Footer